Companies ›Healthcare ›140410.KQ

140410.KQ — KOSDAQ Pharmaceuticals

Mezzion Pharma Co Ltd

$73 900,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-212,9 %

ROE

-203,1 %

Net margin

-441,6 %

Debt / equity

0,69

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Mezzion Pharma Co Ltd is a South Korean pharmaceutical company engaged in the development and commercialization of prescription drugs, primarily in the oncology and rare disease therapeutic areas.

Business. Mezzion Pharma Co Ltd (140410.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments or geographic revenue breakdowns are not disclosed.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-203,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 140410.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 140410.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Mezzion Pharma Co Ltd (140410.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments or geographic revenue breakdowns are not disclosed.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

Mezzion Pharma Co Ltd operates with a capital structure that includes significant cash and equivalents of KRW 25,573,447,000, which is partially offset by a high level of long-term debt of KRW 11,872,924,990. The company's liquidity position is characterized as low, with a current ratio of 0.57, indicating that its current liabilities exceed its current assets. This liquidity constraint is further underscored by negative operating and free cash flows of KRW -16,588,063,310 and KRW -47,213,544,920, respectively.

The company's profitability is currently negative, with a net loss of KRW -34,928,862,370 and a return on equity of -203.14%. These figures are significantly below the industry median for pharmaceutical companies, which typically exhibit positive returns on equity and assets. The negative return on assets of -35.63% further highlights the company's underperformance relative to its peers.

Geographically, Mezzion Pharma's revenue is concentrated in South Korea, with no disclosed international revenue segments. The company's business is primarily driven by its oncology and rare disease drug portfolio, with no material diversification across therapeutic areas or geographic markets.

Looking ahead, the company is expected to continue facing financial challenges, with no significant revenue growth projected in the current or next fiscal year. The capital expenditure of KRW -13,272,797,550 indicates ongoing investment in R&D and infrastructure, but this is not yet translating into positive financial outcomes.

The risk assessment for Mezzion Pharma Co Ltd indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow suggest a high operational risk. The dilution potential is currently low, with no near-term pressure expected, and no recent issuance or ATM/shelf disclosures indicating dilution risk.

Recent filings and transcripts have not revealed any material events that would significantly alter the company's financial trajectory. The company remains focused on its core therapeutic areas, with no disclosed strategic shifts or major partnerships that would impact its financial outlook.

Key takeaways

Mezzion Pharma Co Ltd is a South Korean pharmaceutical company with a focus on oncology and rare disease drugs.
The company is currently experiencing significant financial losses, with a net loss of KRW -34,928,862,370 and a return on equity of -203.14%.
Despite having substantial cash reserves, the company's liquidity position is weak, with a current ratio of 0.57 and negative operating and free cash flows.
The company's revenue is concentrated in South Korea, with no material international presence or diversification.
No immediate liquidity or dilution risks have been identified, but the company's financial performance remains a concern.
The company is expected to continue facing financial challenges in the near term, with no significant revenue growth projected.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$73 900,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$17.19B

Net cashⓘ

$13.70B

Current ratioⓘ

0.6

Debt / equityⓘ

0.7

ROAⓘ

-35.6%

ROEⓘ

-2.0%

Cash conversionⓘ

47.0%

CapEx / revenueⓘ

-1.7%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-212,9 %Bottom quartile

Net Margin-441,6 %Bottom quartile

ROE-203,1 %Bottom quartile

Capex / Rev-167,8 %Bottom quartile

D/E0,69Bottom quartile

Cash Conv0,47Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Mezzion Pharma Co Ltd Market data — financials · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

140410.KQCanonical

KOSDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread